文献速递脑血管病神经重症与神经感染

活动性恶性肿瘤患者脑出血后的血肿周围水肿研究

Perihematomal Edema After Intracerebral Hemorrhage in Patients With Active Malignancy.
PubMed 文献 · Stroke · 2019-11-20

本研究回顾性分析了80例活动性恶性肿瘤合并脑出血患者与136例无活动性癌症的脑出血对照者,发现癌症患者血肿周围水肿体积显著增大,水肿增长与血肿体积和血小板输注相关,30天死亡率与水肿和血肿体积及血制品输注相关。

要点

  • 活动性癌症患者脑出血后血肿周围水肿体积显著高于无癌症对照者。
  • 癌症患者水肿增长与血肿体积和血小板输注独立相关,与血小板减少无关。
  • 30天死亡率与血肿体积、水肿体积、水肿增长及血制品输注相关。

核心结论

  • 活动性癌症患者发生脑出血后血肿周围水肿体积增加,水肿增长与血制品输注相关,30天死亡率与水肿和血肿体积及血制品输注相关。

研究设计与样本

  • 回顾性研究,通过机构数据库自动搜索识别活动性恶性肿瘤合并脑出血患者80例,对照为无活动性癌症的脑出血患者136例。
  • 采用半自动方法测定血肿和血肿周围水肿体积,并建立单变量和多变量线性回归模型。

主要发现

  • 癌症患者血肿周围水肿体积为23.67 mL,对照组为8.61 mL,差异有统计学意义(P=1.88×10-9)。
  • 癌症患者水肿与血肿体积比为2.26,对照组为0.99,差异有统计学意义(P=2.20×10-16)。
  • 癌症患者30天死亡率为36%(n=29)。
  • 多变量分析中,癌症患者水肿增长与血肿体积(β=1.29 [95% CI, 1.58-1.30] P=1.30×10-5)和血小板输注(β=15.67 [95% CI, 3.61-27.74] P=0.014)相关。
  • 30天死亡率与血肿体积(OR 1.06 [95% CI, 1.03-1.10] P=6.76×10-5)、水肿体积(OR 1.07 [95% CI, 1.04-1.09] P=7.40×10-6)、水肿增长(OR 1.05 [95% CI, 1.01-1.10] P=0.01)和血小板输注(OR 1.48 [95% CI, 1.22-1.79] P=0.0001)相关。

关键数值与推荐

  • 癌症患者中位血小板计数为90 000(四分位距17 500-211 500),51%(n=41)接受血制品输注,其中48%(n=38)接受血小板输注。
  • 癌症患者中56%(n=45)近期接受化疗,54%(n=43)存在恶性肿瘤复发。

临床怎么用

  • 对活动性恶性肿瘤合并脑出血患者应关注血肿周围水肿体积及其增长。
  • 血制品输注(尤其血小板输注)可能与水肿增长和30天死亡率相关,临床决策需综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Patients with active malignancy are at risk for intracerebral hemorrhage (ICH). We aimed to characterize perihematomal edema (PHE) and hematoma volumes after spontaneous nontraumatic ICH in patients with cancer without central nervous system involvement. Methods- Patients with active malignancy who developed ICH were retrospectively identified through automated searches of institutional databases. Control patients were identified with ICH and without active cancer. Demographic and cancer-specific data were obtained by chart review. Hematoma and PHE volumes were determined using semiautomated methodology. Univariate and multivariate linear regression models were created to assess which variables were associated with hematoma and PHE expansion. Results- Patients with cancer (N=80) and controls (N=136) had similar demographics (all P>0.20), although hypertension was more prevalent among controls (P=0.004). Most patients with cancer had received recent chemotherapy (n=45, 56%) and had recurrence of malignancy (n=43, 54%). Patients with cancer were thrombocytopenic (median platelet count 90 000 [interquartile range, 17 500-211 500]), and most had undergone blood product transfusion (n=41, 51%), predominantly platelets (n=38, 48%). Thirty-day mortality was 36% (n=29). Patients with cancer had significantly increased PHE volumes (23.67 versus 8.61 mL; P=1.88×10-9) and PHE-to-ICH volume ratios (2.26 versus 0.99; P=2.20×10-16). In multivariate analyses, variables associated with PHE growth among patients with cancer were ICH volume (β=1.29 [95% CI, 1.58-1.30] P=1.30×10-5) and platelet transfusion (β=15.67 [95% CI, 3.61-27.74] P=0.014). Variables associated with 30-day mortality were ICH volume (odds ratio, 1.06 [95% CI, 1.03-1.10] P=6.76×10-5), PHE volume (odds ratio, 1.07 [95% CI, 1.04-1.09] P=7.40×10-6), PHE growth (odds ratio, 1.05 [95% CI, 1.01-1.10] P=0.01), and platelet transfusion (odds ratio, 1.48 [95% CI, 1.22-1.79] P=0.0001). Conclusions- Patients with active cancer who develop ICH have increased PHE volumes. PHE growth was independent of thrombocytopenia but associated with blood product transfusion. Thirty-day mortality was associated with PHE and ICH volumes and blood product transfusion.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Gusdon AM, Nyquist PA, Torres-Lopez VM, et al. Perihematomal Edema After Intracerebral Hemorrhage in Patients With Active Malignancy. Stroke. 2019. PMID: 31744426. doi:10.1161/STROKEAHA.119.027085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。